Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Global Market Report 2025

The temperature-stable messenger ribonucleic acid (mRNA) vial market size has grown rapidly in recent years. It will grow from $1.77 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth during the historic period can be attributed to the rising demand for cold chain logistics, increased adoption of mRNA vaccines, growing government funding for vaccine storage, expansion of global vaccination programs, and the surge in clinical trials targeting infectious diseases.

The temperature-stable messenger ribonucleic acid (mRNA) vial market size is expected to see rapid growth in the next few years. It will grow to $3.33 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to the rising demand for temperature-stable formulations, increasing focus on reducing cold chain expenses, growing adoption of mRNA therapies in oncology, expansion of global immunization initiatives, and rising investments in biopharmaceutical research and development (R&D). Key trends during this period include advancements in formulation science, innovations enabling cold chain-free delivery, developments in lyophilized mRNA vials, enhanced stability testing methods, and the digitalization of supply chain monitoring.

The increasing participation in global vaccination is expected to drive the growth of the temperature-stable messenger ribonucleic acid (mRNA) vial market. Vaccines stimulate the body’s immune system to build protection against specific diseases, and global vaccination efforts are expanding through international collaboration that ensures equitable access and distribution. Temperature-stable mRNA vials facilitate these efforts by allowing easier storage, transportation, and distribution without relying on complex cold chain systems, supporting wider accessibility and sustained immunization coverage. For example, in October 2025, Gavi, a US-based international organization providing vaccines to children in developing countries, reported that DTP3 vaccine coverage in Gavi-supported lower-income countries rose to 82%, up from 80% in 2023, approaching pre-pandemic levels. This growing participation in global vaccination is therefore fueling demand for temperature-stable mRNA vials.

Companies in this market are focusing on innovation to improve manufacturing efficiency and global accessibility. Technology transfer models, which involve sharing expertise and manufacturing techniques to enable local production, are being adopted to expand production capacity and distribute vaccines more broadly. For instance, in January 2024, Germany-based SCHOTT Pharma launched EVERIC freeze vials, capable of withstanding temperatures as low as -80°C, suitable for mRNA and gene therapy products. Their strength-optimized design reduces breakage risk, preventing loss of critical medications and minimizing downtime.

In February 2023, Netherlands-based 20Med Equipment Solutions partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance RNA and DNA vaccine technologies. The collaboration focuses on bio-responsive nanoparticle technology to eliminate the need for frozen storage of mRNA vaccines, enhancing global vaccine accessibility. CEPI, a Norway-based organization, supports innovations such as temperature-stable mRNA vials to improve vaccine storage, distribution, and reach worldwide.

Major players in the temperature-stable messenger ribonucleic acid (mrna) vial market are Arcturus Therapeutics Holdings Inc., CureVac AG, Sanofi S.A., Lonza Group AG, Gerresheimer AG, Stevanato Group, Schott AG, CSafe Global, Gennova Biopharmaceuticals Ltd., TTP Group, Peli BioThermal LLC, SiO2 Materials Science, Shijiazhuang Xinfuda Medical Packaging, Vaxess Technologies, Ethris, Lyophilization Techniques, 20Med Therapeutics BV, EnsiliTech, HDT Bio Corp., and Emervax.

North America was the largest region in the temperature-stable messenger ribonucleic acid (mRNA) vial market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in temperature-stable messenger ribonucleic acid (mRNA) vial report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The temperature-stable messenger ribonucleic acid (mRNA) vial market research report is one of a series of new reports that provides temperature-stable messenger ribonucleic acid (mRNA) vial market statistics, including temperature-stable messenger ribonucleic acid (mRNA) vial industry global market size, regional shares, competitors with a temperature-stable messenger ribonucleic acid (mRNA) vial market share, detailed temperature-stable messenger ribonucleic acid (mRNA) vial market segments, market trends and opportunities, and any further data you may need to thrive in the temperature-stable messenger ribonucleic acid (mRNA) vial industry. This temperature-stable messenger ribonucleic acid (mRNA) vial market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A temperature-stable messenger ribonucleic acid (mRNA) vial is a specially engineered container designed to preserve the stability and efficacy of mRNA formulations without the need for ultra-cold storage. By employing advanced stabilization technologies, these vials protect the delicate mRNA molecules from degradation at higher temperatures, facilitating easier handling, broader distribution, and more reliable use of mRNA-based products.

The primary types of temperature-stable mRNA vials include lipid nanoparticle formulations, polymer-based formulations, lyophilized mRNA vials, and other variants. Lipid nanoparticle formulations encapsulate and safeguard mRNA molecules, enabling efficient delivery into cells. These vials are distributed through direct sales, distributors, online channels, and other avenues. They are applied in vaccines, therapeutics, research, and related fields and are utilized by hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, among other end-users.

The countries covered in the temperature-stable messenger ribonucleic acid (mRNA) vial market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The temperature-stable messenger ribonucleic acid (mRNA) vial consists of sales of stoppers, seals, caps, labels, and packaging materials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.